Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study
Authors' conclusion
Lipid monitoring frequency in T2DM may be individualized by baseline LDL-C level, with intervals of approximately 16-24, 9-15, and 2-8 months representing minimum frequencies.
Study context
- Population
- Adults with T2D and no prior cardiovascular disease (CVD) with ≥2 lipid panel tests within any 12-month window during 2009–2012, Hong Kong Hospital Authority; stratified by baseline LDL-C (<1.8, 1.8–2.59, ≥2.6 mmol/L)
- Comparison
- Lipid monitoring every 2-8 vs 9-15 vs 16-24 months, within baseline LDL-C strata
- Outcome
- All-cause mortality and major CVD
- Follow-up
- Until 31 December 2021
Methodological detailsclone-censor-weight approach, three-arm, territory-wide electronic health records, stratified by baseline LDL-C
- Clone-censor-weight approach
- Three-arm
- Territory-wide electronic health records
- Stratified by baseline LDL-C
Main finding
As reported in the abstract
Each group vs 2-8 monthsHazard ratio (95% CI)
16-24 monthsLDL-C < 1.8 mmol/L; mortality
1.094(0.948–1.263)
16-24 monthsLDL-C < 1.8 mmol/L; CVD
1.002(0.846–1.187)
16-24 monthsLDL-C 1.8-2.59 mmol/L; mortality
1.154(1.069–1.245)
9-15 monthsLDL-C ≥ 2.6 mmol/L; mortality
1.263(1.174–1.359)
9-15 monthsLDL-C ≥ 2.6 mmol/L; CVD
1.060(1.017–1.105)
Original publication
Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study. Diabetes Res Clin Pract. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →